217 related articles for article (PubMed ID: 16928833)
41. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
42. Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Chang YW; Singh KP
Eur J Pharm Sci; 2018 Oct; 123():56-69. PubMed ID: 30016648
[TBL] [Abstract][Full Text] [Related]
43. Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.
Lv J; Fu Z; Shi M; Xia K; Ji C; Xu P; Lv M; Pan B; Dai L; Xie H
Biomed Pharmacother; 2015 Feb; 69():162-9. PubMed ID: 25661353
[TBL] [Abstract][Full Text] [Related]
44. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
45. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
Wang Z; Kong J; Wu Y; Zhang J; Wang T; Li N; Fan J; Wang H; Zhang J; Ling R
Breast Cancer Res Treat; 2018 Apr; 168(2):531-542. PubMed ID: 29185119
[TBL] [Abstract][Full Text] [Related]
46. FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer.
Xing M; Wang J; Yang Q; Wang Y; Li J; Xiong J; Zhou S
Cancer Chemother Pharmacol; 2019 Oct; 84(4):861-872. PubMed ID: 31428819
[TBL] [Abstract][Full Text] [Related]
47. Signal transduction pathways in Burkitt's lymphoma cell lines BL41 and DG75 with different sensitivity to doxorubicin.
Shlapatska LM; Berdova GG; Kovalevska LM; Kulyk GI; Klein G; Sidorenko SP; Chekhun VF
Exp Oncol; 2004 Sep; 26(3):210-6. PubMed ID: 15494689
[TBL] [Abstract][Full Text] [Related]
48. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
[TBL] [Abstract][Full Text] [Related]
49. Blockage of cytosolic phospholipase A2 alpha sensitizes aggressive breast cancer to doxorubicin through suppressing ERK and mTOR kinases.
Li Z; Qu M; Sun Y; Wan H; Chai F; Liu L; Zhang P
Biochem Biophys Res Commun; 2018 Jan; 496(1):153-158. PubMed ID: 29307829
[TBL] [Abstract][Full Text] [Related]
50. Xanthohumol, a Prenylated Chalcone from Hops, Inhibits the Viability and Stemness of Doxorubicin-Resistant MCF-7/ADR Cells.
Liu M; Yin H; Qian X; Dong J; Qian Z; Miao J
Molecules; 2016 Dec; 22(1):. PubMed ID: 28036030
[TBL] [Abstract][Full Text] [Related]
51. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
[TBL] [Abstract][Full Text] [Related]
52. Comparative study of human breast carcinoma MCF-7 cells differing in their resistance to doxorubicin: effect of ionizing radiation on apoptosis and TGF-beta production.
Chorna I; Bilyy R; Datsyuk L; Stoika R
Exp Oncol; 2004 Jun; 26(2):111-7. PubMed ID: 15273662
[TBL] [Abstract][Full Text] [Related]
53. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
54. Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells.
Zhang Z; Lin G; Yan Y; Li X; Hu Y; Wang J; Yin B; Wu Y; Li Z; Yang XP
Oncogene; 2018 Jun; 37(25):3456-3470. PubMed ID: 29559745
[TBL] [Abstract][Full Text] [Related]
55. Altered cell cycle response of drug-resistant lung carcinoma cells to doxorubicin.
O'Loughlin C; Heenan M; Coyle S; Clynes M
Eur J Cancer; 2000 Jun; 36(9):1149-60. PubMed ID: 10854949
[TBL] [Abstract][Full Text] [Related]
56. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
[TBL] [Abstract][Full Text] [Related]
57. Overcoming doxorubicin-resistance in the NCI/ADR-RES model cancer cell line by novel anthracene-9,10-dione derivatives.
Sangthong S; Ha H; Teerawattananon T; Ngamrojanavanich N; Neamati N; Muangsin N
Bioorg Med Chem Lett; 2013 Nov; 23(22):6156-60. PubMed ID: 24095089
[TBL] [Abstract][Full Text] [Related]
58. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
59. Protein arginine methyltransferase 1 may be involved in pregnane x receptor-activated overexpression of multidrug resistance 1 gene during acquired multidrug resistant.
Li T; Kong AN; Ma Z; Liu H; Liu P; Xiao Y; Jiang X; Wang L
Oncotarget; 2016 Apr; 7(15):20236-48. PubMed ID: 26934120
[TBL] [Abstract][Full Text] [Related]
60. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
